Treat to target in gout
| Autor: | Alastair J. Dickson, Fernando Perez-Ruiz, Aitana Moreno-Lledó, Irati Urionagüena |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
musculoskeletal diseases
congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty Gout Gout Suppressants 03 medical and health sciences 0302 clinical medicine Rheumatology Quality of life Internal medicine Good evidence medicine Humans Pharmacology (medical) 030212 general & internal medicine 030203 arthritis & rheumatology Systemic lupus erythematosus business.industry nutritional and metabolic diseases Disease Management Treat to target Evidence-based medicine medicine.disease Uric Acid business |
| Zdroj: | Rheumatology (Oxford, England). 57(suppl_1) |
| ISSN: | 1462-0332 |
| Popis: | The treat-to-target (T2T) approach has been successfully implemented in a number of diseases. T2T has been proposed for rheumatic diseases such as RA, spondyloarthritis, lupus, and recently for gout. The level of evidence for such approaches differs from one condition to the other (moderate to high for hyperlipidaemia, for example). Practice is based on the best available evidence at any time, and in absence of good evidence for T2T in gout, some suggest a conservative only-treat-symptoms approach. Evidence suggests that not treating gout to target in the long term is overall associated with worsening outcomes, such as flares, tophi and structural damage, which is associated to loss of quality of life and mortality. Different targets have been proposed for hyperuricaemia in gout; lower than 6 mg/dl (0.36 mmol/l) for all patients, at least |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|